Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	29.86	18.53	19.13	19.99	5.74	-
Cash & Short-Term Investments	29.86	18.53	19.13	19.99	5.74	-
Cash Growth	53.43%	-3.10%	-4.34%	248.19%	-	-
Other Current Assets	0.28	0.07	0.06	0.41	0.09	-
Total Current Assets	30.15	18.61	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	-	0.82	-
Total Assets	30.15	18.61	19.19	20.41	6.66	-
Accounts Payable	2.99	2.5	2.77	2.91	1.06	0.01
Accrued Expenses	5.9	6.4	4.21	2.83	0.54	-
Other Current Liabilities	0.3	-	-	0.45	0.82	-
Total Current Liabilities	9.19	8.89	6.98	6.19	2.42	0.01
Total Liabilities	9.19	8.89	6.98	6.19	2.42	0.01
Additional Paid-In Capital	99.53	82.96	66.45	46.2	1.89	-
Retained Earnings	-78.58	-73.25	-54.25	-31.99	-12.9	-0.01
Total Common Equity	20.95	9.71	12.2	14.22	-11.01	-0.01
Shareholders' Equity	20.95	9.71	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	30.15	18.61	19.19	20.41	6.66	-
Net Cash (Debt)	29.86	18.53	19.13	19.99	5.74	-
Net Cash Growth	53.43%	-3.10%	-4.34%	248.19%	-	-
Net Cash Per Share	1.66	1.08	1.23	1.58	1.35	-
Filing Date Shares Outstanding	23.63	23.39	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	23.63	19.5	17.42	14.64	4.51	3.9
Working Capital	20.95	9.71	12.2	14.22	3.41	-0.01
Book Value Per Share	0.89	0.50	0.70	0.97	-2.44	-0.00
Tangible Book Value	20.95	9.71	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.89	0.50	0.70	0.97	-2.44	-0.00

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q